2016-10-01
CARD: A randomized phase 4 trial comparing cabazitaxel and an androgen receptor (AR)-targeted agent in men with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and an alternative AR-targeted agent
Publication
Publication
Annals of Oncology
,
Volume 27
p. vi262
| Additional Metadata | |
|---|---|
| Persistent URL | dx.doi.org/10.1093/annonc/mdw372.50, hdl.handle.net/1765/125589 |
| Journal | Annals of Oncology |
| Citation |
de Wit, R, Fizazi, K, Efstathiou, E, Dittamore, R. (R.), Hitier, S. (S.), Pantel, K, … de Bono, J.S. (2016). CARD: A randomized phase 4 trial comparing cabazitaxel and an androgen receptor (AR)-targeted agent in men with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and an alternative AR-targeted agent. Annals of Oncology, 27. doi:10.1093/annonc/mdw372.50
|